| Nov 13 |
Intensity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
|
| Nov 13 |
3 US Penny Stocks With Market Caps Under $200M To Watch
|
| Nov 8 |
Intensity Therapeutics Selected for Oral Podium Presentation in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society (Sarcomas) Meeting
|
| Oct 31 |
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Announce the First Patient Dosed in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 / SAKK 66/22)
|
| Aug 9 |
Intensity Therapeutics GAAP EPS of -$0.36
|
| Aug 8 |
Intensity Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
|
| Jul 9 |
Intensity Therapeutics, Inc. Announces First Patient Dosed in its Global Randomized, Phase 3 Study (INVINCIBLE-3) in Metastatic Soft Tissue Sarcoma
|
| Jun 6 |
Will Intensity Therapeutics (NASDAQ:INTS) Spend Its Cash Wisely?
|
| May 15 |
Intensity Therapeutics, Inc. Announces the Appointment of Thomas Dubin to Its Board of Directors
|
| May 14 |
Intensity Therapeutics: A Bargain For A Late-Stage Company With A Remarkable Oncology Drug
|
